Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oral nutritional supplement rich in eicosapentanoic acid
- Development stage
- Unknown
- Lead developer
- Charité Universitätsmedizin Berlin
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
This oral nutritional supplement (ONS) is a protein- and energy-dense formulation enriched with eicosapentaenoic acid (EPA), an omega-3 polyunsaturated fatty acid. Developed and evaluated in clinical trials by Charite University, Berlin, it is primarily indicated for the management of malnutrition and cancer cachexia in patients with gastrointestinal tumors, including colorectal, hepatocellular, and cholangiocarcinoma. EPA acts as an anti-catabolic and anti-inflammatory agent by modulating the systemic inflammatory response. It competes with arachidonic acid for cyclooxygenase (COX) and lipoxygenase (LOX) enzymes, thereby reducing the production of pro-inflammatory 2-series prostaglandins and 4-series leukotrienes, which are associated with muscle wasting and weight loss in malignant diseases.
- Other names
- EPA-enriched oral nutritional supplementomega-3 fatty acid-enriched nutritional supplementomega3 fatty acid-enriched nutritional supplementomega 3 fatty acid-enriched nutritional supplementoral nutritional supplement rich in eicosapentanoic acid
02
Targets
ALOX5 (Arachidonate 5-lipoxygenase)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PPARA (Peroxisome proliferator-activated receptor alpha)
Beyond the preview
Go deeper on oral nutritional supplement rich in eicosapentanoic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oral nutritional supplement rich in eicosapentanoic acid.